Proposal Summary for Interested Organizations: Lung Cancer Screening

AMGA is gathering interest from member organizations on a quality improvement proposal submission. Please review the overview below and if interested, we would love to coordinate an informational call to discuss further. Note- a non-binding letter of commitment would be required in October 2024 if your organization would wish to participate.

Project Title: Early Detection and Diagnosis to Improve the Care of People at Risk of Non-Small Cell Lung Cancer (NSCLC)

Timeline: Anticipated January 2025- June 2026

Summary: Member organizations, with support from AMGA and a team of advisors, will implement a quality improvement initiative to improve the care of people at risk of NSCLC, specifically through improving screening and use of biomarker testing to aid in diagnosis.

Site Expectations:

- Engagement of multi-disciplinary team within health system and integration of patient perspective.
- Complete a root cause analysis to identify processes and methods to maximize effectiveness of interventions to improve screening and testing for lung cancer.
- Develop and implement intervention(s) to support early screening and comprehensive biomarker testing.
- Ability and willingness to submit de-identified, system or clinical level, EHR data to AMGA to support evaluation of baseline, interim, and post implementation.
- Share learnings from intervention and implementation process.

What AMGA will provide:

- Project management and analytic support including project preparation, protocol development, measure development, milestones management, analytics, and benchmarking with other participating organizations.
- Opportunities for shared learning from expert advisors and peers.

Primary outcomes:

- Proportion of patients diagnosed with NSCLC in early- vs. advanced/metastatic stage.
- Proportion of patients who receive care to facilitate detection of NSCLC (e.g., screening according to USPSTF recommendations, work up of lung nodules).
- Proportion of patients with suspected or diagnosed lung cancer who receive comprehensive biomarker testing.